FDA identifies companies ‘potentially blocking access’ to drug samples

21-05-2018

FDA identifies companies ‘potentially blocking access’ to drug samples

carmendorin / iStockphoto.com

The US Food and Drug Administration (FDA) has published a list of companies that it suspects might be preventing generic drug producers accessing samples of branded products.


USFDA, generic drugs, US Food and Drug Administration, Tracleer (bosentan), Revlimid (lenalidomide), competition

LSIPR